Padma Portono 
Interns and mentors are finishing their summer research with the Indiana Center for Biomedical Innovation (ICBI) this month. The program supports Indiana Clinical and Translational Sciences Institute’s goal of teaching undergraduate students while giving them hands-on training in translational research and entrepreneurship. Read more…
Scioto Biosciences, a preclinical stage company developing innovative therapies to transform the delivery of microbiome therapeutics, today announced that they are a recipient of a Phase II SBIR grant from the National Institutes of Health (NIH) for $2.3 million. The Phase II award is to continue to support the research with Scioto’s collaborator, the Abigail … Read more
The federal government provides various supports for health ventures to strengthen the country’s public health and innovation-driven economy. Dr. H. Timothy Hsiao, the Program Director at the National Center for Advancing Translational Sciences, discussed NIH’s relevant sources of funding and technical assistance, including but not limited to the: Small Business Technology Transfer (R41/R42), Small Business … Read more
Meet the Q2 solutions team at the Indiana Center for Biomedical Innovation (ICBI), Thursday, May 23rdat noon Q2 Solutions is a global clinical trial laboratory service organization Early Hit-to-Lead ADME Screening Services offered by Q2
The Indiana Philanthropic Venture Fund (IU PhV) is on the doorstep of its one-year anniversary and, although not limited to the life sciences, it has funneled $1.6 million into the sector’s early-stage Indiana-based companies. Its visionaries designed the evergreen fund to be a “perpetual resource” and an answer for Indiana University alums who want to … Read more
The First Academic Entrepreneur-Investor Forum Indiana Center for Biomedical Innovation (ICBI) is hosting the “Entrepreneur-Investor Forum” on October 16th, 2018. The goal of the event is to bring together the key organizations involved in life sciences entrepreneurial ecosystem in Indianapolis and catalyze collaboration to promote commercialization of life science technologies. The event will be organized in partnership … Read more
ICBI welcomes HB Therapeutic, Inc., which just received the NIH/NCI SBIR phase I grant of $300,000 for development of the company first small molecule degraders of small ubiquitin-like modifier-1 protein (SUMO1) as new anticancer drugs. Founded by Dr. Bellail and Dr. Hao in 2015, HB Therapeutics is a biotech company for discovery and development of … Read more
